Clinical Trials

October 29, 2024

Explore iadademstat for AML treatment in Oryzon Genomics' latest clinical trials with promising results.

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

October 09, 2024

Explore the AMpLify trial testing CRISPR-edited CAR-T therapy CB-012 for relapsed/refractory AML, now recruiting patients for Phase 1.

September 30, 2024

Learn about clinical trials to open the door to accessing innovative cancer treatments.

September 16, 2024

Promising new off-the-shelf CAR NK cell therapy, SENTI-202, offers hope for relapsed/refractory AML & MDS. Learn about eligibility and trial locations.

July 12, 2024

AML specialist Harry Erba, MD, PhD, shared insight about a new treatment decision-making model for AML and MDS patients called myeloMATCH.

May 16, 2024

Here we take a look at the drug, gemtuzumab ozogamicin, and its efficacy on relapsed or refractory AML.

March 06, 2024

Bisantrene has shown significant advancement in the treatment of R/R AML.

October 17, 2023

Better tolerated and more effective therapies are needed for the treatment of AML.

October 10, 2023

E-selectin is a biomarker that is currently being investigated for its efficacy in AML treatment.